Who are Intravenous rhPro-UK's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, tPA, Retaane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-rhpro-uk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous rhPro-UK — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous rhPro-UK (Intravenous rhPro-UK) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombolytic agent. Area: Cardiovascular.

phase 3 Thrombolytic agent Plasminogen Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous rhPro-UK (Intravenous rhPro-UK) — First Affiliated Hospital Xi'an Jiaotong University. Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous rhPro-UK TARGET	Intravenous rhPro-UK	First Affiliated Hospital Xi'an Jiaotong University	phase 3	Thrombolytic agent	Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
tPA	tPA	Life Recovery Systems	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen (converts to plasmin)
Retaane	anecortave		marketed	anecortave	Plasminogen activator inhibitor 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombolytic agent class)

First Affiliated Hospital Xi'an Jiaotong University · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous rhPro-UK — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-rhpro-uk. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab